UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Precision cut lung slices: an integrated ex vivo model for studying lung physiology, pharmacology, disease pathogenesis and drug discovery

Respiratory research, 2024-06, Vol.25 (1), p.231-21

2024

Volltextzugriff (PDF)

Rhinovirus C15 Attenuates Relaxation and cAMP Production in Human Airways and Smooth Muscle

American journal of respiratory cell and molecular biology, 2023-08, Vol.69 (2), p.172-181

2023

Volltextzugriff (PDF)

Airway smooth muscle and airway hyperresponsiveness in asthma: mechanisms of airway smooth muscle dysfunction

Minerva medica, 2022-02, Vol.113 (1), p.4

2022

Volltextzugriff (PDF)

Differential Effect of Non-Thermal Plasma RONS on Two Human Leukemic Cell Populations

Cancers, 2021-05, Vol.13 (10), p.2437

2021

Volltextzugriff (PDF)

CEBPD modulates the airway smooth muscle transcriptomic response to glucocorticoids

Respiratory research, 2022-07, Vol.23 (1), p.193-14, Article 193

2022

Volltextzugriff (PDF)

Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse

Journal of clinical oncology, 2010-07, Vol.28 (20), p.3323-3329

2010

Volltextzugriff (PDF)

2174: Single versus multi-fraction SABR for early-stage primary lung and pulmonary oligometastases

Radiotherapy and oncology, 2024-05, Vol.194, p.S1722-S1724

2024

Volltextzugriff (PDF)

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

The lancet oncology, 2017-09, Vol.18 (9), p.1274-1284

2017

Volltextzugriff (PDF)

Personal innovative approach in radiation therapy of lung cancer- functional lung avoidance SPECT-guided (ASPECT) radiation therapy: a study protocol for phase II randomised double-blind clinical trial

BMC cancer, 2021-08, Vol.21 (1), p.1-9, Article 940

2021

Volltextzugriff (PDF)

Discordance between GCIG CA-125 progression and RECIST progression in the CALYPSO trial of patients with platinum-sensitive recurrent ovarian cancer

British journal of cancer, 2024-02, Vol.130 (3), p.425-433

2024

Volltextzugriff (PDF)

Reporting the trajectories of adverse events over the entire treatment course in patients with recurrent platinum-sensitive ovarian cancer treated with platinum-based combination chemotherapy regimens: A graphical approach to trial adverse event reporting

European journal of cancer (1990), 2021-05, Vol.148, p.251-259

2021

Volltextzugriff (PDF)

Cut‐point for Ki‐67 proliferation index as a prognostic marker for glioblastoma

Asia-Pacific journal of clinical oncology, 2019-02, Vol.15 (1), p.5-9

2019

Volltextzugriff (PDF)

Value of central review of RECIST v1.1 outcomes in the AGITG INTEGRATE randomised phase 2 international trial for advanced oesophago-gastric cancer

Journal of cancer research and clinical oncology, 2023-07, Vol.149 (8), p.4959-4965

2023

Volltextzugriff (PDF)

Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy

European journal of cancer (1990), 2021-09, Vol.154, p.190-200

2021

Volltextzugriff (PDF)

Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapy

European journal of cancer (1990), 2019-08, Vol.117, p.99-106

2019

Volltextzugriff (PDF)

Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: Analysis of the CALYPSO trial

Gynecologic oncology, 2015-01, Vol.136 (1), p.18-24

2015

Volltextzugriff (PDF)

Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer

JNCI : Journal of the National Cancer Institute, 2011-09, Vol.103 (17), p.1338-1342

2011

Volltextzugriff (PDF)

Concordance between CA-125 and RECIST progression (PD) in patients with germline BRCA-mutated platinum-sensitive, relapsed ovarian cancer treated with a PARP inhibitor (PARPi) as maintenance therapy after response to chemotherapy

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.6014-6014

2020

Volltextzugriff (PDF)

Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial

Gynecologic oncology, 2017-01, Vol.144 (1), p.65-71

2017

Volltextzugriff (PDF)

Quality of life (QOL) to predict overall survival (OS) in women with platinum-resistant ovarian cancer (PROC)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.5575-5575

2016

Volltextzugriff (PDF)

Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study

BMC cancer, 2014-12, Vol.14 (1), p.897-897, Article 897

2014

Volltextzugriff (PDF)

Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline (g) BRCA-mutated (m) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): SOLO2 phase III trial

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.5507-5507

2017

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(28)

Sprache

Englisch
(28)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(20)
Science & Technology
(20)
Humans
(16)
Oncology
(16)
Female
(10)
Adult
(9)
Middle Aged
(9)
Chemotherapy
(8)
Ovarian Cancer
(8)
Ovarian Neoplasms - Drug Therapy
(8)
Aged
(7)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(7)
Clinical Trials
(6)
Patients
(6)
Platinum
(6)
Tumors
(6)
Aged, 80 And Over
(5)
Cancer
(5)
Cancer Therapies
(5)
Neoplasm Recurrence, Local - Drug Therapy
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Precision cut lung slices: an integrated ex vivo model for studying lung physiology, pharmacology, disease pathogenesis and drug discovery

Rhinovirus C15 Attenuates Relaxation and cAMP Production in Human Airways and Smooth Muscle

Airway smooth muscle and airway hyperresponsiveness in asthma: mechanisms of airway smooth muscle dysfunction

Differential Effect of Non-Thermal Plasma RONS on Two Human Leukemic Cell Populations

CEBPD modulates the airway smooth muscle transcriptomic response to glucocorticoids

Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse

2174: Single versus multi-fraction SABR for early-stage primary lung and pulmonary oligometastases

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial

Personal innovative approach in radiation therapy of lung cancer- functional lung avoidance SPECT-guided (ASPECT) radiation therapy: a study protocol for phase II randomised double-blind clinical trial

Discordance between GCIG CA-125 progression and RECIST progression in the CALYPSO trial of patients with platinum-sensitive recurrent ovarian cancer

Reporting the trajectories of adverse events over the entire treatment course in patients with recurrent platinum-sensitive ovarian cancer treated with platinum-based combination chemotherapy regimens: A graphical approach to trial adverse event reporting

Cut‐point for Ki‐67 proliferation index as a prognostic marker for glioblastoma

Value of central review of RECIST v1.1 outcomes in the AGITG INTEGRATE randomised phase 2 international trial for advanced oesophago-gastric cancer

Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy

Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapy

Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy

A nomogram to predict progression-free survival benefit with maintenance olaparib and bevacizumab following response to first line chemotherapy in advanced ovarian cancer (305)

Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: Analysis of the CALYPSO trial

Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer

Concordance between CA-125 and RECIST progression (PD) in patients with germline BRCA-mutated platinum-sensitive, relapsed ovarian cancer treated with a PARP inhibitor (PARPi) as maintenance therapy after response to chemotherapy

Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial

Quality of life (QOL) to predict overall survival (OS) in women with platinum-resistant ovarian cancer (PROC)

Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study

Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline (g) BRCA-mutated (m) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): SOLO2 phase III trial

Suchergebnisse filtern